Form 8-K - Current report:
SEC Accession No. 0001193125-24-285627
Filing Date
2024-12-27
Accepted
2024-12-27 09:05:53
Documents
18
Period of Report
2024-12-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d865206d8k.htm   iXBRL 8-K 36151
2 EX-4.1 d865206dex41.htm EX-4.1 71968
3 EX-10.1 d865206dex101.htm EX-10.1 184902
4 EX-10.2 d865206dex102.htm EX-10.2 77938
5 EX-99.1 d865206dex991.htm EX-99.1 11784
9 GRAPHIC g865206g1227120512626.jpg GRAPHIC 2525
  Complete submission text file 0001193125-24-285627.txt   621916

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA vor-20241226.xsd EX-101.SCH 2837
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE vor-20241226_lab.xml EX-101.LAB 18739
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vor-20241226_pre.xml EX-101.PRE 11700
20 EXTRACTED XBRL INSTANCE DOCUMENT d865206d8k_htm.xml XML 3767
Mailing Address 100 CAMBRIDGEPARK DRIVE SUITE 101 CAMBRIDGE MA 02140
Business Address 100 CAMBRIDGEPARK DRIVE SUITE 101 CAMBRIDGE MA 02140 617-655-6580
Vor Biopharma Inc. (Filer) CIK: 0001817229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39979 | Film No.: 241582689
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)